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Panhypogammaglobulinemia as-
sociated with bronchiectasis in the
present case are classic ﬁndings of
CVID that explain the repeated episodes
of pneumonia. Unresponsiveness to di-
arrhea was initially thought to be a distal
UC, which, unusually, was hard to con-
trol; however, the almost normal fea-
tures on endoscopic (colonoscopy) and
histological controls associated with the
rapid and sustained positive response af-
ter the ﬁrst gamma globulin infusion,
allowing the withdrawal of the steroid
and azathioprine, suggest that the gas-
trointestinal disorders were probably
caused by the underlying overlap immu-
nodeﬁciency process.
Besides the present case, we also
have 2 others with CVID among 150
patients whose cases we have followed in
our IBD outpatient unit. One of them has
ileocolitis CD without symptoms of im-
munodeﬁciency: the diagnosis was made
just by chance during immunological
screening. The second patient was initially
diagnosed with classic CIVD and was
kept on regular gammaglobulin infusions.
Later, the investigation of gastrointestinal
symptoms resulted in the detection of his-
tological IC. More recently he has devel-
oped liver and biliary enzyme elevations
(primary sclerosing cholangitis?), as well
as splenomegaly and mesenteric lymph
nodes (lymphoma?) that are under inves-
tigation.
These cases, particularly the 1 de-
scribed in depth here, highlight the need to
be aware of the possibility of immunode-
ﬁciency disorders in IBD patients (as the
cause or as a consequence, we do not
know yet), who may develop unusual re-
sponses to common therapeutic applica-
tions, or an overlap process of recurrent
infections, or any autoimmune disease, or
cancer.
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Posttransplant
Lymphoproliferative
Disorders in Patients
with IBD on
Immunosuppressive
Treatment
To the Editor:
We read with great interest the
article by San Roman et al1 in the Jour-
nal of Crohn’s & Colitis (JCC) reporting
on a case of a primary rectal large cell
B-lymphoma associated with Epstein–
Barr virus (EBV) infection, occurring in
a patient with ulcerative colitis (UC)
treated with azathioprine and inﬂiximab.
The occurrence of posttransplant
lymphoproliferative disorders (PTLDs)
in patients with inﬂammatory bowel dis-
ease (IBD) treated with immunosup-
pressives (IS) has been a matter of great
concern to us in the last 5 years, as we
managed 3 cases of PTLD in patients
with IBD, all on azathioprine. At our
department, a referral center for IBD in
Portugal, over 700 patients are regularly
seen as in- or outpatients. About 56%
and 20% of our patients with Crohn’s
disease (CD) and UC, respectively, are
currently on IS, mainly with azathio-
prine or 6-mercaptopurine (6-MP), with
22% and 2%, in the same order, also
being treated with inﬂiximab. We had
no other cases of lymphoma, namely,
non-Hodgkin’s, Hodgkin’s, or other rare
types.
The ﬁrst case occurred in 2003 in
a 34-year-old female with a 6-year ste-
roid-dependent extensive UC (E3). She
was treated with azathioprine (2.0–3.3
mg/kg/day) for 5 years, except for a
short period in 1999 when she had a
unique inﬂiximab infusion and was on
mycophenolate mofetil (20 mg/kg/day)
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for 6 months. In 2003 she was admitted
for a severe ﬂare (S3) with concomitant
oral candidiasis, herpetic esophagitis,
and perirectal abscess related to a previ-
ously known rectovaginal ﬁstula. She
was ﬁrst stabilized with medical treat-
ment and then proposed for proctocolec-
tomy. The resection specimen revealed,
along with a low-activity ulcerative pan-
colitis, a monotonous towel-spreading
lymphoid population deeply inﬁltrating
the rectal wall up to the perirectal fat. It
consisted mainly of pleomorphic B cells
(CD20 and CD30), some marking
positively for EBV (LMP1). The ﬁnal
diagnosis was a diffuse large cell B-
lymphoma associated with EBV. The
second case emerged in a 35-year-old
male with an 18-year left-sided (E2)
UC, treated chronically with aminosa-
licylates (5-ASA, 1.5 g/day) and with
azathioprine (1.4 mg/kg/day) for 1 year.
The disease had had a generally benign
course until 1 year before, when lesions
of pioderma gangrenosum appeared on
his left leg and azathioprine was started.
In 2005 he was admitted for hematoche-
zia, abdominal pain, and low-grade fe-
ver (37.5°C) starting the day before
(S2). Colonoscopy showed an ulcerated
circumferential nonstenosing lesion at
the sigmoid colon, with histology show-
ing a lymphoid population similar to
that described in the ﬁrst case. Total
proctocolectomy was performed and an
EBV-positive diffuse large cell B-lym-
phoma of the sigmoid colon was con-
ﬁrmed. The third case also occurred in
2005, in a 22-year-old female with a
steroid-dependent A1, L3, B2 CD,
treated with inﬂiximab (5 mg/kg every 8
weeks) for 2 years and azathioprine
(2.0–2.2 mg/kg/day) for 9 years. She
had an asymptomatic stenosis at the
splenic ﬂexure known for 7 years, reg-
ularly evaluated on colonoscopy. In
2005 histological examination of the
stenosis revealed an EBV-positive poly-
morphic polyclonal lympho-plasmacy-
thoid population which was classiﬁed as
an early PTLD, subtype infectious
mononucleosis (IM)-like. This ﬁnding
prompted suspension of azathioprine.
Biopsies taken 2 months later showed
only chronic colitis features and PTLD
appeared to have suffered regression.
However, new sampling taken 8 months
after azathioprine stoppage again de-
picted an EBV-positive polymorphic
lymphoid population, now with numer-
ous blast cells suggesting progression to
polymorphic lymphoma. Resection of
the splenic ﬂexure was undertaken. Sur-
prisingly, the resection specimen did not
conﬁrm the latter ﬁndings, yet showed
features of a more benign early PTLD,
subtype plasmacytic hyperplasia. In all 3
cases no spreading disease was found on
resected nodes, bone marrow examina-
tion, and computed tomography (CT)
scanning of the chest, abdomen, and pel-
vis. All patients are regularly seen on
hematology and sustain remission of the
disease. None resumed azathioprine.
The patient reported last is currently on
inﬂiximab and in remission of CD.
The type of lymphoma reported
by San Roman et al and in the ﬁrst 2
cases reported here is one of the ma-
lignant PTLDs according to the World
Health Organization classiﬁcation.2–4
As discussed by San Roman et al, they
comprise benign and malignant EBV-
driven lymphoid proliferations devel-
oping as a consequence of IS treatment
in allograft recipients2–4 that were also
described in patients with rheumatoid
arthritis (RA) treated with methotrex-
ate.1 We emphasize that these lesions
had been reported in patients with IBD
as well, speciﬁcally in those treated
with azathioprine or 6-MP.5,6 More-
over, a recent cohort study implicated
such medications in the doubling of
EBV-associated lymphomas, with an
absolute risk of PTLD of 0.5% for
patients with IBD treated with azathio-
prine or 6-MP.7 Yet even if this ﬁgure
was reproducible for other popula-
tions, it would be of little signiﬁcance
when compared to the beneﬁt obtained
with these drugs.8 PTLDs are poorly
understood lesions both in transplant
recipients and in RA and IBD patients.
Staging and treatment options are
mostly adapted from non-Hodgkin’s
lymphoma, with the major exception
being that a reduction on the IS level is
the mainstay of treatment, sometimes
inducing remission of early PTLD by
itself.2,3 This latter event occurred in
the third case reported, although evi-
dence of regression warranted surgery.
Indeed, despite the confounding
8-month biopsies suggesting progres-
sion to lymphoma, the ﬁnal diagnosis
(plasmacytic hyperplasia PTLD) is be-
lieved to be more benign than IM-like
PTLD, which may occasionally
progress to lymphoma.3 Likewise, re-
gression of PTLD to a more benign
type occurred after IS stoppage on San
Roman et al’s report. However, we
should stress that polymorphic hyper-
plasia, also termed polymorphic B-
lymphoma, does not always have a
benign behavior, at least in the trans-
plant setting. They have an intermedi-
ate behavior and have a variable re-
sponse to IS reduction.3 Thus,
although we generally agree that sus-
pension of IS and surgery seemed the
most correct approach for the reported
case, we diverge for the absolutely
benign nature of the lesion found in
the resection specimen.
In conclusion, our experience of
lymphoma occurring in IBD is limited
to 3 (4.5%) cases of PTLD in patients
on azathioprine for at least 1 year.
PTLDs are poorly understood dis-
eases. Classiﬁcation, treatment op-
tions, and prognostic considerations
are still based on limited knowledge
obtained in transplant recipients who
have major differences compared to
patients with IBD. As such, we pro-
pose that these patients should not
only be treated with a multidisci-
plinary approach as proposed by San
Roman et al, but should also be man-
aged by a multidisciplinary team. e.g.,
pathologists, gastroenterologists, sur-
geons, hematologists/oncologists, and
therapeutic radiation experts.
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Inﬂiximab for Severe
Gastrointestinal Bleeding
in Crohn’s Disease
To the Editor:
Severe lower gastrointestinal (GI)
bleeding is a rare but potentially life-
threatening complication of Crohn’s dis-
ease (CD), occurring in 0.9% to 6% of
cases.1–4 Although bleeding can occur in
a ﬂare-up of the disease, patients with
CD sometimes complain of the sudden
onset of bloody stool without any dete-
rioration of the other symptoms.1,2
When the bleeding site can be identiﬁed
by colonoscopy, bleeding is mostly at-
tributable to colonic ulcers or ulcerated
areas.1 We describe a patient with CD
presenting with severe lower GI bleed-
ing in whom inﬂiximab induced rapid
mucosal healing and prevented recurrent
bleeding.
A 16-year-old girl, who had been
suffering from CD involving the colon
for 1 year, was referred to our hospital
because of bloody stool and lower ab-
dominal pain. CD was well controlled
with mesalazine (2250 mg/day) until 1
month before this admission. Physical
examination on admission showed
slight pain and tenderness at the peri-
umbilical region without muscular
guarding. Rectal examination revealed
fresh bloody stool. Bowel sounds were
normal. Laboratory values were as fol-
lows: white blood cell count, 15,400/
mm3; hematocrit, 37.5%; hemoglobin,
12.0 g/dL; albumin, 3.3 g/dL; and C-
reactive protein, 5.36 mg/dL. Colonos-
copy revealed multiple large and deep
ulcers in the colon (Fig. 1a). Small
intestinal series showed no abnormal-
ities. We treated her with an increased
dose of mesalazine (3000 mg/day) and
prednisolone (40 mg/day) on total par-
enteral nutrition, resulting in rapid im-
provement of the symptoms.
Eight days later the patient sud-
denly lapsed into hemorrhagic shock
because of the sudden onset of mas-
sive bloody stool and her hemoglobin
dropped to 5.2 g/dL. Although urgent
angiography after 6 units of blood
transfusion could not detect a bleeding
site, GI bleeding scintigraphy dis-
closed an uptake at the sigmoid colon.
Colonoscopy showed diffuse mucosal
inﬂammation with multiple deep ul-
cers in the colon. Because we could
not discover the deﬁnite bleeding site,
and colonic mucosa did not improve
after therapy, we treated her with a
single infusion of inﬂiximab (5 mg/kg)
to achieve mucosal healing and to stop
and prevent the bleeding. Three days
after the inﬂiximab infusion her symp-
toms disappeared, and colonoscopy
showed rapid improvement of mucosal
inﬂammation. One month later muco-
sal healing was observed without co-
lonic strictures (Fig. 1b). Although the
patient refused the maintenance ther-
apy with inﬂiximab, no recurrent
bleeding has occurred for 1 year.
The management of severe GI
bleeding in CD is a therapeutic chal-
lenge.1–3 Although several approaches
such as medical therapy, endoscopic
treatment, angiographic intervention,
and surgical resection have been at-
tempted to control bleeding, multiple
and diffuse bleeding as in our patient
does not allow for these approaches,
and the recurrence rate of bleeding is
high.1–4 Because most bleeding origi-
nates from severe mucosal lesions
such as colonic ulcers or ulcerated ar-
eas, achieving mucosal healing is the
therapeutic goal to prevent recurrent
bleeding.1,3 This goal can be obtained
by surgical resection, but medical ther-
apy of CD with conventional drugs
such as steroids and immunomodula-
tors does not have a consistent endo-
scopic improvement.1
Recently, several studies reported
that the antitumor necrosis factor-alpha
antibody, inﬂiximab, is effective for re-
fractory CD.2,5 Although repeated in-
ﬂiximab infusions can induce rapid and
sustained mucosal healing,1,5,6 there is
little evidence on whether inﬂiximab in-
fusion is effective for acute and massive
GI bleeding in CD. In our patient, ste-
roids therapy was ineffective, and recur-
rent bleeding occurred because of per-
sistent mucosal inﬂammation with
multiple ulcers. The infusion of inﬂix-
imab stopped severe GI bleeding, and
promoted rapid mucosal healing result-
ing in no recurrent bleeding. Because
this therapy induces rapid effects, and
may avoid surgical resection for uncon-
trolled bleeding, we believe that inﬂix-
imab therapy should be considered for
acute and massive GI bleeding in CD
before surgery.
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